AU565 Xenograft Model Service for Breast Cancer

The AU565 xenograft model provides an essential in vivo platform for studying HER2-amplified breast cancer, enabling precise evaluation of targeted therapies and overcoming resistance mechanisms in a clinically relevant context. As a specialized CRO, Alfa Cytology delivers high-quality, reproducible AU565 xenograft services, leveraging our deep oncology expertise to accelerate your drug discovery pipeline from concept to actionable in vivo data.

Overview of AU565 Xenograft Model for Breast Cancer

The AU565 xenograft model is derived from the AU565 human breast adenocarcinoma cell line. Its primary defining characteristic is the significant amplification and overexpression of the HER2/neu (ERBB2) oncogene, making it a foundation for research into HER2-positive breast cancer, which constitutes approximately 15-30% of all breast cancer cases clinically. The model is highly proliferative and tumorigenic when inoculated into immunocompromised mice (such as Balb/c Nude or SCID), forming solid tumors that retain the key molecular signature of the patient's disease. This model is particularly valuable because, like many clinical cases, it expresses the p95HER2 truncated form, which is associated with resistance to certain HER2-targeted agents like trastuzumab. Consequently, the AU565 model is widely utilized to test novel antibody-drug conjugates (ADCs), tyrosine kinase inhibitors (TKIs), combination therapies designed to overcome resistance, and to study the downstream signaling pathways (like PI3K/AKT and MAPK) driven by HER2 overexpression in vivo.

Fig 1. The mean and standard deviation on the AU565 and MDA-MB-231 (MDA231) tumor models from the first imaging session using the iodine contrast agent. (Li M, et al., 2024)

Cell Line Information: AU565

The AU565 cell line was established from a pleural effusion of a 43-year-old Caucasian female patient with metastatic breast carcinoma. It is closely related to the SK-BR-3 cell line, sharing the same patient origin but exhibiting distinct features regarding sensitivity to certain treatments and resistance profiles. AU565 is characterized as an epithelial cell line that grows rapidly in culture and exhibits robust tumor growth when established as an in vivo xenograft.

Our Services

Workflow of AU565 Xenograft Model Construction

Constructing a robust AU565 xenograft model requires precise execution across several critical stages:

• Cell Preparation: AU565 cells are cultured in vitro using optimized media. Cells are harvested during the exponential growth phase to ensure maximum viability and the preservation of the HER2-overexpressing phenotype.
• Animal Selection & Acclimatization: Health-certified, immunocompromised female mice are selected as hosts. Animals are acclimatized to the SPF-grade facility environment according to institutional animal welfare guidelines.
• Inoculation: A calibrated suspension of AU565 cells, supplemented with a basement membrane matrix to enhance tumorigenicity, is injected subcutaneously into the flank or orthotopically into the mammary fat pad of the mice.
• Tumor Monitoring: Following inoculation, animals are monitored daily for clinical health. Tumor growth is tracked through regular measurements of tumor volume and body weight to establish a predictable growth curve.
• Randomization & Dosing: Once the tumors reach a pre-determined target volume, mice are randomized into treatment and control groups based on tumor size to ensure statistical parity before the therapeutic regimen begins.

Fig 2. AU565 Xenograft Model Construction Workflow

Case Study - AU565 Xenograft Model Development

In a recent preclinical development program, Alfa Cytology successfully established the AU565 xenograft model to evaluate a novel anti-HER2 Antibody-Drug Conjugate (ADC). The model exhibited a highly consistent tumor take rate and robust, predictable growth kinetics, allowing tumors to reach the randomization threshold within an efficient timeframe. The study effectively demonstrated potent tumor growth inhibition (TGI) in the treatment group compared to controls, while maintaining stable animal body weights throughout the study duration.

Why Choose Alfa Cytology?

• HER2 Expertise: Deep understanding of HER2 signaling and resistance pathways.
• Reproducible Results: Standardized protocols ensure uniform tumor growth and reliable efficacy data.
• Customized Study Design: Flexible protocols tailored to your unique compound and therapeutic objectives.
• Comprehensive Readouts: Full integration of in vivo data with PK/PD and biomarker analysis.

Contact Us

Ready to accelerate your HER2-targeted breast cancer therapy program with precisely executed in vivo data? Our oncology team is waiting to discuss your specific requirements. We invite you to reach out to us today to explore how the AU565 xenograft model service at Alfa Cytology can drive your pipeline forward. Please contact us directly or complete the inquiry form below to receive a consultation and personalized project proposal.

For research use only. Not intended for any clinical use.